Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What is the current market size of the breast cancer screening test industry, and what growth rate is it expected to achieve?
The breast cancer screening test market size has grown strongly in recent years. It will grow from $2.31 billion in 2024 to $2.51 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to increasing reimbursement policies, rising focus on preventive healthcare, rising health consciousness, increasing research and development, and rising awareness about early detection.
The breast cancer screening test market size is expected to see strong growth in the next few years. It will grow to $3.46 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to the increasing incidence of breast cancer, growing government initiatives, rising healthcare expenditure, expansion of mobile screening units, and growing female population. Major trends in the forecast period include advancements in imaging technology, the development of non-invasive screening methods, advancements in genetic testing, genomic testing advancements, and the development of mobile screening solutions.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24180&type=smp
What are the major drivers contributing to the growth of the breast cancer screening test market?
The rising breast cancer incidence is expected to propel the growth of the breast cancer screening test market going forward. Breast cancer is the uncontrolled growth of abnormal cells in the breast tissue, which can form a tumor and potentially spread to other parts of the body. The rise in breast cancer is due to the aging global population, as advancing age is a major risk factor for the disease, and longer life expectancies mean more individuals. Breast cancer screening tests help detect the disease at an early stage, increasing the chances of successful treatment and reducing breast cancer-related mortality. For instance, in March 2025, according to Breastcancer.org, a US-based nonprofit organization, around 316,950 women are expected to have a diagnosis of invasive breast cancer in 2025, while 59,080 new cases of non-invasive ductal carcinoma in situ (DCIS) are going to be reported. Moreover, in December 2024, according to the Public Health Agency of Canada, a Canada-based government agency, an estimated 28,600 Canadian women are expected to get a breast cancer diagnosis in 2022, and 5,500 may lose their lives to the disease. Therefore, the rising breast cancer incidence rates are driving the growth of the breast cancer screening test market.
What are the major market segments driving the growth of the breast cancer screening test industry?
The breast cancer screening test market covered in this report is segmented –
1) By Diagnostic Test Type: Blood Marker Test, Imaging Test, Genetic Test, Immunohistochemistry Test
2) By Risk Level: High-risk Population, Moderate-risk Population, Average-risk Population
3) By End User: Hospitals, Diagnostic Centres, Cancer Institutes, Research Laboratories
Subsegments
1) By Blood Marker Test: Circulating Tumor Cells (Ctcs) Test, Gene Expression Profiling Test, Circulating Tumor Dna (Ctdna) Test, Proteomic Biomarker Test
2) By Imaging Test: Mammography, Magnetic Resonance Imaging Screening Test, Molecular Breast Imaging Test, Positron Emission Tomograph Scan, Ultrasound
3) By Genetic Test: Fluorescence In Situ Hybridization, Her Gene Test
4) By Immunohistochemistry (Ihc) Test: Estrogen Receptor (Er) Test, Ki-67 Proliferation Marker Test, Progesterone Receptor (Pr) Test, Her2 Or Neu Test
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/breast-cancer-screening-test-global-market-report
What are the key trends shaping the breast cancer screening test market in the forecast period?
Major companies operating in the breast cancer screening test market are focusing on developing innovative products, such as mobile cancer screening units, to enhance accessibility, improve early detection rates, and expand screening coverage in underserved and remote areas. A mobile cancer screening unit is a transportable facility with diagnostic imaging technologies, such as mammography, designed to provide on-site breast cancer screening services in remote or underserved areas. For instance, in September 2024, Granules India Ltd., an India-based pharmaceutical company, launched a Breast Health Express to boost breast cancer screening in underprivileged communities. The unit is equipped with state-of-the-art mammography and ultrasound technology, enabling high-quality screenings on the go. This initiative focuses on reaching underserved and rural communities where access to healthcare facilities may be limited, ensuring that women in remote areas have access to life-saving early detection services.
Who are the key market players contributing to the growth of the breast cancer screening test industry?
Major companies operating in the breast cancer screening test market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthcare GmbH, Fujifilm Corporation, Koninklijke Philips NV, GE HealthCare Technologies Inc., Quest Diagnostics Incorporated, Hologic Inc., Hitachi High-Tech Corporation, Exact Sciences Corporation, Natera Inc., Myriad Genetics Inc., Canon Medical Systems Corporation, Provista Diagnostics Inc., POC Medical Systems Inc., Niramai Health Analytix Pvt. Ltd., Kheiron Medical Technologies Limited, UE LifeSciences Inc., Dxcover Limited
Which regions are leading the growth of the breast cancer screening test market globally?
North America was the largest region in the breast cancer screening test market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer screening test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Breast Cancer Screening Test Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24180&type=smp
Need Customized Data On Breast Cancer Screening Test Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24180&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
